WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2010144140) EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/144140 International Application No.: PCT/US2010/001670
Publication Date: 16.12.2010 International Filing Date: 10.06.2010
IPC:
A61K 39/395 (2006.01) ,A61K 31/7105 (2006.01) ,A61P 3/10 (2006.01) ,A61P 1/04 (2006.01) ,A61P 37/00 (2006.01)
Applicants: FASANO, Alessio[US/US]; US (UsOnly)
LAMMERS, Karen[NL/US]; US (UsOnly)
SHEA-DONOHUE, Terez[US/US]; US (UsOnly)
GOLDBLUM, Simeon[US/US]; US (UsOnly)
UNIVERSITY OF MARYLAND, BALTIMORE[US/US]; 620 West Lexington Street, 4th Floor Baltimore, MD 21201-1627, US (AllExceptUS)
Inventors: FASANO, Alessio; US
LAMMERS, Karen; US
SHEA-DONOHUE, Terez; US
GOLDBLUM, Simeon; US
Agent: ADLER, Benjamin, Aaron; Adler & Associates 8011 Candle Lane Houston, TX 77071, US
Priority Data:
61/185,66210.06.2009US
Title (EN) EGFR AND PAR2 REGULATION OF INTESTINAL PERMEABILITY
(FR) RÉGULATION PAR EGFR ET PAR2 DE LA PERMÉABILITÉ INTESTINALES
Abstract:
(EN) The present invention provides a method of treating an autoimmune disease, comprising the steps of increasing transepithelial electrical resistance leading to decreased cell permeability. Further provided is ajnethod of treating celiac disease in an individual in need of such treatment, comprising the steps of: administering an antibody directed against single chain zonulin thereby inhibiting epidermal growth factor receptor and inhibiting PAR2.
(FR) La présente invention concerne un procédé de traitement d'une maladie auto-immune, comprenant les étapes d'augmentation de la résistance électrique transépithéliale permettant de réduire la perméabilité cellulaire. Elle concerne également un procédé de traitement d'une maladie cœliaque chez un individu nécessitant un tel traitement, comprenant les étapes d'administration d'un anticorps dirigé contre la zonuline à une seule chaîne qui a pour effet d'inhiber le récepteur du facteur de croissance épidermique et d'inhiber PAR2.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)